2023 IASLC North America Conference on Lung Cancer Satellite Symposia
PER's Breast Cancer Symposia in San Antonio
Leukemia Therapy – A Look Into the Future
2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition
Reflective Case-Based Oncology Collective: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care
Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers
Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care
Oncology nurses should be ready to offer informative guidance to patients and their families concerning the ongoing FDA inquiry and its potential impact.
The FDA has granted enfortumab vedotin plus pembrolizumab priority review status for patients with locally advanced or metastatic urothelial cancer following data from the phase 3 EV-302/KEYNOTE-A39 trial.
The median overall survival was 77.5 months with frontline pembrolizumab vs 36.7 months with chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer.
The FDA has approved the non-covalent BTK inhibitor, pirtobrutinib, to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already undergone 2 lines of therapy.
Pembrolizumab, in addition to enzalutamide and androgen deprivation therapy, was not associated with better radiographic progression-free survival outcomes in patients with metastatic hormone-sensitive prostate cancer.
Patients with prostate cancer who received 18 months of androgen deprivation therapy were more likely to recover their serum testosterone levels and to recover quicker than those who received 36 months of therapy.